GlassScriptPhysician profile
Ashley Seaton
NPI 1811491657
$6,846.94
in general payments reported to CMS, 2019-2025
38 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $600 · 2022: $1,647 · 2023: $1,564 · 2024: $1,599 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,599.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,290.42 | 2021-2025 | |
| Amgen INC. | $693.59 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Novo Nordisk INC | $570.54 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $502.07 | 2021-2025 | Airsupra, Farxiga, Tezspire |
| Glaxosmithkline, LLC. | $499.32 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $451.06 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $377.38 | 2021-2024 | |
| Lilly USA, LLC | $323.06 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $285.26 | 2021-2024 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.30 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $168.27 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.27 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Lundbeck LLC | $136.99 | 2022-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $121.73 | 2022 | |
| Axsome Therapeutics, INC. | $108.28 | 2024-2025 | Auvelity |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $103.06 | 2022-2023 | |
| Esperion Therapeutics, INC. | $95.46 | 2021-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $75.12 | 2024 | Givlaari |
| Bausch Health US, LLC | $72.71 | 2021-2022 | |
| Corium, LLC | $60.91 | 2023 | Adlarity |
| Kowa Pharmaceuticals America, INC. | $55.09 | 2021-2025 | Zoryve |
| Antares Pharma, INC. | $54.82 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Exact Sciences Corporation | $52.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $46.11 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $46.05 | 2021 | |
| Dexcom, INC. | $43.30 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $30.78 | 2021-2023 | Belsomra |
| Sanofi-Aventis U.S. LLC | $28.52 | 2023 | |
| Boston Scientific Corporation | $23.53 | 2025 | General - Erectile Dysfunction |
| Corcept Therapeutics | $23.43 | 2025 | Korlym |
| Inogen, INC. | $22.65 | 2022 | |
| Nevro Corp. | $20.80 | 2023 | Senza |
| Dynavax Technologies Corporation | $15.26 | 2024 | Heplisav-B |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2025 | Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.27 | 2025 | Caplyta |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.24 | 2021 | |
| Astellas Pharma US INC | $12.92 | 2023 | Veozah |
| Neurocrine Biosciences, INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Seaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.